Encouraging Results from Phase 1 Trials, Says Satellos Chief Scientific Officer. Now It's On to Phase 2

In this third segment of an interview with Managed Healthcare Executive, Phil Lambert, chief scientific officer for Satellos Bioscience Inc., discussed the clinical trials of its experimental treatment for Duchenne muscular dystrophy. The treatment, named SAT-3247 for now, is a small-molecule drug that targets muscle stem cells with the intention of triggering the process that leads to muscle regeneration.

Lambert described the results of a phase 1 dosing trial in healthy volunteers to assess safety as "very clean." Those results were presented in March 2025 at the MDA Clinical & Scientific Conference.

On May 22, 2025, Satellos announced results of phase 1b that enrolled five men with Duchenne muscular dystrophy. The company's news release said the data from that trial showed that the drug was well tolerated and had the expected pharmacokinetics. Although the trial was not designed to assess efficacy, the news release says the data suggest early signs of improved grip strength, a measure of efficacy.

Lambert emphasized the phase 1 data pointing to the safety of SAT-3247. "As is always the case with phase 1 trials, the focus was on safety. And with PK [pharmacokinetics], we wanted to make sure the drug translated from preclinical to clinical in the way we would have predicted. We wanted to make sure, of course, that it was safe, as you always have to do. And we wanted to make sure that that was true in the patients as well as the healthy volunteers, because there is a lot going on in a complex disease [such as Duchenne]."

The company is putting together its phase 2 program, Lambert said. "We are looking to be as time efficient as we can because we realize how important this is for patients," he said.